特应性湿疹 Recap 问卷(RECAP)的效度、信度、反应度与可解释性
在荷兰三级医院前瞻性纳入200例成人特应性皮炎患者,于基线、1-3天后和4-12周后完成RECAP问卷及参照工具。RECAP单评分效度良好、反应度中等、信度极好,提出控制程度分段及≥6分界定未控制、改善≥4分为临床重要变化。
要点
- RECAP单评分效度良好(82%先验假设成立),反应度中等(59%假设成立),信度极好(ICCagreement 0.988)。
- 控制程度分段:0-1分完全控制,2-5分大部分控制,6-11分中度控制,12-19分少许控制,20-28分完全未控制。
- ≥6分可识别AD未控制患者,改善≥4分代表临床重要变化,支持RECAP用于常规临床与研究。
核心结论
- RECAP具有良好单评分效度、中等反应度和极好信度,本研究填补了其可解释性空白。
- 结果提示≥6分可识别AD「未控制」患者,改善≥4分代表临床重要变化。
- 鉴于Eczema Harmonising Outcome Measures initiative的认可,结果支持将RECAP整合入常规临床实践和研究环境。
研究设计与样本
- 在荷兰一家三级医院开展前瞻性研究,于2021年6月至2022年12月招募成人AD患者。
- 患者在基线、1-3天后和4-12周后三个时间点完成RECAP问卷、参照工具和锚定问题。
- 共纳入200名参与者(男性占57.5%,平均年龄38.5岁)。
主要发现
- 先验假设中单评分效度82%被确认,反应度59%被确认。
- 已知组分析显示,基于疾病严重度和生活质量损害分组的患者间RECAP评分存在差异。
- SEMagreement为1.17分,ICCagreement为0.988。
- 未观察到地板效应或天花板效应。
- SDC为3.2分,预测模型法得出的MIC值为3.9分。
关键数值与推荐
- 最终分段:0-1分完全控制;2-5分大部分控制;6-11分中度控制;12-19分少许控制;20-28分完全未控制。
- 单一截断值≥6分用于识别AD未控制患者。
- SDC为3.2分,预测模型法MIC值为3.9分。
- MIC估计采用四种基于锚定的方法:均值变化法、95%限值切点、ROC曲线和预测建模。
临床怎么用
- RECAP可用于成人AD患者报告结局的评估,≥6分提示AD未控制。
- 改善≥4分可视为临床重要变化。
- 研究结果支持将RECAP整合入常规临床实践和研究环境。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited research has been conducted on the measurement properties of the Recap of atopic eczema (RECAP) questionnaire, particularly in relation to interpretability. OBJECTIVES: To investigate the validity, reliability, responsiveness and interpretability of the Dutch RECAP in adults with atopic dermatitis (AD). METHODS: We conducted a prospective study in a Dutch tertiary hospital, recruiting adults with AD between June 2021 and December 2022. Patients completed the RECAP questionnaire, reference instruments and anchor questions at the following three timepoints: baseline, after 1-3 days and after 4-12 weeks. Hypotheses testing was used to investigate single-score validity and change-score validity (responsiveness). To assess reliability, both standard error of measurement (SEMagreement) and intraclass correlation coefficient (ICCagreement) were reported. To assess the interpretability of single scores, bands for eczema control were proposed. To investigate the interpretability of change scores, both smallest detectable change (SDC) and minimally important change (MIC) scores were determined. To estimate the MIC scores, four different anchor-based methods were employed: the mean change method, 95% limit cut-off point, receiver operating characteristic curve and predictive modelling. RESULTS: In total, 200 participants were included (57.5% male sex, mean age 38.5 years). Of the a priori hypotheses, 82% (single-score validity) and 59% (responsiveness) were confirmed. Known-group analyses showed differences in the RECAP scores between patient groups based on disease severity and impairment of the quality of life. The SEMagreement was 1.17 points and the ICCagreement was 0.988. The final banding was as follows: 0-1 (completely controlled); 2-5 (mostly controlled); 6-11 (moderately controlled); 12-19 (a little controlled); 20-28 (not at all controlled). Moreover, a single cut-off point of ≥ 6 was determined to identify patients whose AD is not under control. The SDC was 3.2 points, and the MIC value from the predictive modelling was 3.9 points. Neither floor nor ceiling effects were observed. CONCLUSIONS: The RECAP has good single-score validity, moderate responsiveness and excellent reliability. This study fills a gap in the interpretability of the RECAP. Our results indicate a threshold of ≥ 6 points to identify patients whose AD is 'not under control', while an improvement of ≥ 4 points represents a clinically important change. Given its endorsement by the Harmonising Outcome Measures for Eczema initiatives, the results of this study support the integration of RECAP into both routine clinical practice and research settings.
引用
- Zhang J, Ragamin A, Romeijn GLE, et al. Validity, reliability, responsiveness and interpretability of the Recap of atopic eczema (RECAP) questionnaire. Br J Dermatol. 2023. PMID: 37463409. doi:10.1093/bjd/ljad247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。